260 related articles for article (PubMed ID: 18363993)
1. Strategies and challenges in eliciting immunity to melanoma.
Ferguson AR; Nichols LA; Zarling AL; Thompson ED; Brinkman CC; Hargadon KM; Bullock TN; Engelhard VH
Immunol Rev; 2008 Apr; 222():28-42. PubMed ID: 18363993
[TBL] [Abstract][Full Text] [Related]
2. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
3. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
[TBL] [Abstract][Full Text] [Related]
4. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
6. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J
J Immunother; 2003; 26(5):432-9. PubMed ID: 12973032
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
8. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
9. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes.
Nichols LA; Chen Y; Colella TA; Bennett CL; Clausen BE; Engelhard VH
J Immunol; 2007 Jul; 179(2):993-1003. PubMed ID: 17617591
[TBL] [Abstract][Full Text] [Related]
10. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
12. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
Roberts EW; Broz ML; Binnewies M; Headley MB; Nelson AE; Wolf DM; Kaisho T; Bogunovic D; Bhardwaj N; Krummel MF
Cancer Cell; 2016 Aug; 30(2):324-336. PubMed ID: 27424807
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
14. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
Berard F; Blanco P; Davoust J; Neidhart-Berard EM; Nouri-Shirazi M; Taquet N; Rimoldi D; Cerottini JC; Banchereau J; Palucka AK
J Exp Med; 2000 Dec; 192(11):1535-44. PubMed ID: 11104796
[TBL] [Abstract][Full Text] [Related]
15. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
[TBL] [Abstract][Full Text] [Related]
16. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.
Matheoud D; Baey C; Vimeux L; Tempez A; Valente M; Louche P; Le Bon A; Hosmalin A; Feuillet V
PLoS One; 2011 Apr; 6(4):e19104. PubMed ID: 21552572
[TBL] [Abstract][Full Text] [Related]
18. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
19. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
